Adc Therapeutics Sa Stock Price, News & Analysis

ADC Therapeutics announced updated Phase 2 trial data for ZYNLONTA in treating relapsed/refractory marginal zone lymphoma (r/r MZL) at ICML 2025. The trial showed impressive results with an 84.6% overall response rate and 69.2% complete response rate among 26 evaluable patients. Notably, 17 of 18 patients maintained complete response, with the longest duration being 27 months. The progression-free survival rate was 92.9% at 12 months. The treatment demonstrated a manageable safety profile, with mostly grade 1 or 2 adverse events. The study is expanding to additional sites to increase enrollment to 50 patients, and ADC Therapeutics plans to pursue regulatory pathways based on continued positive results.

ADC Therapeutics (NYSE: ADCT) has secured a $100 million PIPE financing through the sale of 13.0 million common shares at $3.53 per share and pre-funded warrants for 15.7 million shares at $3.43 each. The funding will support ZYNLONTA's clinical development and commercialization. The company plans significant restructuring, including a 30% workforce reduction and UK facility closure, incurring $6-7 million in restructuring charges. This extends their cash runway into 2028. Key upcoming catalysts include LOTIS-7 trial data expansion, LOTIS-5 Phase 3 trial results, potential regulatory submissions, and advancement of their PSMA-targeting ADC program. The PIPE financing, led by Redmile Group, is expected to close on June 16, 2025.

ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b trial evaluating ZYNLONTA in combination with glofitamab for relapsed/refractory DLBCL patients. The combination demonstrated remarkable efficacy with a 93.3% overall response rate and 86.7% complete response rate among 30 evaluable patients. Notably, 25 of 26 patients achieving complete response maintained it at data cutoff. The treatment showed a manageable safety profile across 41 safety-evaluable patients, with main grade 3+ adverse events including neutropenia (24.4%) and anemia (9.8%). Based on these promising results, the company is expanding the trial enrollment to 100 patients at the 150 µg/kg dose level.

ADC Therapeutics (NYSE: ADCT) has granted stock options to two new employees totaling 107,550 common shares as part of their employment inducement package. The grants, approved by the Company's Compensation Committee under the Inducement Plan, were made on June 2, 2025. The options will vest over a four-year period, with 25% vesting on the first anniversary and the remaining vesting monthly at a rate of 1/48th, contingent on continued employment. The grants were made in compliance with NYSE's Listed Company Manual Rule 303A.08 and aim to motivate high performance and significant contributions to the company's success.

ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), has announced its participation in two upcoming investor conferences. The company's CEO Ameet Mallik will present at the RBC Capital Markets Global Healthcare Conference on May 21, 2025, from 10:30-10:55 a.m. ET, and at the Jefferies Global Healthcare Conference on June 5, 2025, from 9:55-10:25 a.m. ET. Both presentations will be in a fireside chat format and available via webcast on the company's investor relations website, with replays accessible for approximately 30 days after each event.

ADC Therapeutics (NYSE: ADCT) reported Q1 2025 financial results and operational updates. Key highlights include promising LOTIS-7 trial data showing ZYNLONTA® plus glofitamab achieved a 95.5% overall response rate and 90.9% complete response rate in r/r DLBCL patients. The company reached 40-patient enrollment in LOTIS-7 dose expansion arm and expects to provide updates in H2 2025. Financial results show $17.4M in ZYNLONTA product revenues and $5.6M in license revenues. Net loss was $38.6M ($0.36 per share), improved from $46.6M loss in Q1 2024. Cash position stands at $194.7M, expected to fund operations into H2 2026. The company discontinued the ADCT-602 trial for r/r B-cell acute lymphoblastic leukemia based on clinical data.

ADC Therapeutics (NYSE: ADCT) announced promising results from its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA in combination with glofitamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The trial showed remarkable efficacy with an overall response rate of 95.5% and complete response rate of 90.9% among 22 evaluable patients. The study included 31 patients who received ≥1 ZYNLONTA dose, demonstrating a manageable safety profile. Key adverse events included neutropenia (32.3%) as the most common Grade ≥3 TEAE. The data will be presented at both the European Hematology Association 2025 Congress (EHA2025) in Milan and the 18th International Conference on Malignant Lymphoma (ICML) in Lugano.

The company will also present updated LOTIS-5 safety run-in data evaluating ZYNLONTA plus rituximab combination at EHA2025.

ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), has scheduled its first quarter 2025 financial results conference call and webcast for May 14, 2025, at 8:30 a.m. EDT. The company will present financial results and provide business updates during the call.

Participants can join via toll-free dial-in (1-800-836-8184 for North America and Canada) or through a live webcast available on the company's investor relations website. Pre-registration is recommended 10 minutes before the event. The webcast recording will be accessible for 30 days after the call.

ADC Therapeutics (NYSE: ADCT) presented preclinical data for three exatecan-based antibody drug conjugates (ADCs) at the AACR Annual Meeting 2025. The key highlight was ADCT-242, targeting Claudin-6, which demonstrated potent antitumor activity in ovarian and non-small lung cancer models, with good tolerance up to 150 mg/kg in mice and 40 mg/kg in cynomolgus monkeys.

Additionally, ADCT-241, targeting PSMA, showed promising results in prostate cancer models with synergistic effects when combined with enzalutamide. The third ADC, HuB14-VA-PL2202, targeting ASCT2, exhibited potent antitumor activity in both solid and hematological cancer cell lines with good tolerability in preclinical studies.